Navigation Links
New marker identified for early diagnosis of lung cancer
Date:9/16/2013

PHILADELPHIA A protein called isocitrate dehydrogenase (IDH1) is present at high levels in lung cancers and can be detected in the blood, making it a noninvasive diagnostic marker for lung cancers, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"This study is the first to report identification of IDH1 as a novel biomarker for the diagnosis of non-small cell lung cancers (NSCLC) using a large number of clinical samples," said Jie He, M.D., Ph.D., director of the Laboratory of Thoracic Surgery at the Peking Union Medical College and Chinese Academy of Medical Sciences in Beijing. "Lung cancer has a high mortality rate, mostly because of late diagnosis. With an increase in aging population, we are likely to see an increase in lung cancer incidence and a need for better biomarkers for early diagnosis. We have identified IDH1 as an effective plasma biomarker with high sensitivity and specificity in the diagnosis of NSCLC, especially lung adenocarcinoma."

Lung cancer is the leading cause of cancer deaths in both men and women in the United States and worldwide. To detect lung cancer in blood, currently certain biomarkers including CEA, Cyfra21-1 and CA125 are used, but these markers are not very sensitive, according to He.

He and colleagues found that IDH1 could be detected in the blood of lung cancer patients with 76 percent sensitivity and 77 percent specificity. When they used a mathematical model to combine the detection of IDH1 with the detection of existing markers CEA, Cyfra21-1, and CA125, the sensitivity increased to 86 percent.

"Based on the present data, IDH1 can be used to detect stage 1 lung cancer; however, it is also possible that IDH1 could be used to detect precancer but further studies are required to address that possibility," said He.

He and colleagues used blood samples collected from 943 patients with NSCLC and 479 healthy
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Immune System Marker Tied to Improved Bone Marrow Transplant Outcomes
2. Researchers identify novel biomarker for diabetes risk
3. Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence
4. Researchers to identify genetic biomarkers for aggressive breast cancer
5. Study identifies fibroblast growth factor 18 as an ovarian cancer biomarker
6. Molecular marker predicts patients most likely to benefit longest from 2 popular cancer drugs
7. Biomarker assessment in suspected ACS could be practice-changing: BIC-8 results
8. Researchers develop specific tests to identify cancer biomarkers in dermatomyositis
9. Brain dopamine may serve as a risk marker for alcohol use disorders
10. Global Oncology Biomarkers Market to Reach US $9.5 Billion by 2014 at a CAGR of 18.1% - New Report by MarketsandMarkets
11. Biomarker Market is Estimated to Grow at a CAGR of 14.40% During the Study Period of 2011-2016 – New Report by MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... Today marks a significant achievement in bringing new monies into early stage companies. ... a group of experienced investors, has tapped into an investor community passionate about Sofia’s ... part of the fund. The Sofia Fund II is now closed to investors, ...
(Date:7/29/2015)... New York, NY (PRWEB) , ... July 29, 2015 , ... ... Petitions were approved by USCIS over the past month! I-829 approvals have been granted ... projects in Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... the Hackett Hemwall Foundation in March, Steven W. Meier M.D., a prominent orthopedic ... treatments to qualifying patients with demonstrated financial need. , “We are thrilled for ...
(Date:7/29/2015)... AL (PRWEB) , ... July 29, 2015 , ... Employee ... directory will include the general contact information, website, types of plans administered, years in ... their business listing and have at least one plan with Employee Fiduciary. A search ...
(Date:7/29/2015)... ... 29, 2015 , ... TransFlip is an all new dynamic transition pack for ... FCPX, these transitions are easy to apply and modify for any skill-level user. TransFlip ... 60 preset styles, kinetic flipping panel animations are just a few clicks away. , ...
Breaking Medicine News(10 mins):Health News:Sofia Fund Surpasses Investor Goals 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2
... Maureen Salamon HealthDay Reporter , THURSDAY, April 28 ... in her early forties when she developed anorexia nervosa, and ... the middle of a disorder like that, you don,t know ... said. Luckily, Hodgin sought the care of a therapist ...
... arthritis may find themselves taking on a more active role ... an ongoing relationship with a primary healthcare (PHC) provider, according ... current issue of Medical Care , the study is ... a regular primary healthcare provider and patient activation, a growing ...
... MD The Association for Research in Vision and ... of distinguished fellows. The title of Fellow of ARVO ... to the Association. By accepting this honor, ARVO ... models and mentors for individuals pursuing careers in vision ...
... Association for Research in Vision and Ophthalmology (ARVO) is pleased ... will be acknowledged at the ARVO 2011 Annual Meeting, May ... Medal: Robert E. Anderson, MD, PhD, FARVO, Mildred Weisenfeld Award ... FEBOpht, FARVO, Friedenwald Award: James T. Rosenbaum, MD, FARVO, Cogan ...
... during proton treatments for pediatric cancer patients provides for ... radiation compared to standard diagnostic X-rays and cone beam ... Cancer Imaging and Radiation Therapy Symposium in Atlanta. The ... Oncology (ASTRO) and the Radiological Society of North America ...
... with fluorodeoxyglucose positron emission tomography (FDG-PET) images results ... different treatment options in head and neck cancer ... research presented today, at the Cancer Imaging and ... co-sponsored by the American Society for Radiation Oncology ...
Cached Medicine News:Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 3Health News:Ongoing relationship with care provider key for patients with a chronic condition: UBC study 2Health News:2011 ARVO Fellows announced 2Health News:2011 ARVO Award recipients honored at annual meeting 2Health News:2011 ARVO Award recipients honored at annual meeting 3Health News:Proton imaging provides more accuracy, less radiation to pediatric cancer patients 2
(Date:7/29/2015)... , July 29, 2015  Cepheid (Nasdaq: ... an update to Xpert® Carba-R, with the addition ... OXA-232.  The on-demand, molecular test also detects and ... carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and ... as CROs or Superbugs, are a growing and ...
(Date:7/29/2015)... , July 29, 2015  Mylan N.V. (NASDAQ: ... clearance from the European Commission under the European Union ... Company plc (NYSE: PRGO ; TASE).  ... commented, "Today marks yet another important milestone in the ... as further affirmation of the sound industrial logic of ...
(Date:7/29/2015)... , July 29, 2015  Efforts to improve working ... of pharmaceutical firms in North America ... is that an effective working capital management will ease ... patent cliffs. Big pharma companies expect to invest in ... Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO Analysis ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
... Satellite Symposium -, SOUTH SAN FRANCISCO, Calif., ... ), a biopharmaceutical company focused,on oncology, today announced ... prostate cancer patients from its Phase 1 study ... 2008 Genitourinary (GU) Cancers,Symposium, a meeting of the ...
... a landmark study,electronically published today in the American ... test for detecting TB infection,QuantiFERON(R)-TB Gold (QFT(TM)), has ... the conventional tuberculin skin test (TST) at predicting,which ... TB,disease. This study has important implications for the ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 2Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 3Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 4Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients 5Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 2Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 3Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 4
FLEXILOG spare part....
FLEXILOG spare part....
... are available from Oakfield for ... All buffers are suitable for ... external reference, single or multi-use ... in 250ml bottle and pH ...
... kit for convenient pH catheter calibration., ,pH ... any procedure. The Alpine Calibration kit contains ... water for your convenience. Simply cut the ... catheters to soak. No measuring or pouring! ...
Medicine Products: